Quest Diagnostics launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein that can appear years before dementia symptoms arise.
CHICAGO — Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein that can appear years before dementia symptoms arise.
"One of the advantages of having an amyloid test is that it lets you know, potentially years in advance of even being symptomatic, that you are at risk for Alzheimer's," said Dr. Michael Racke, Quest's medical director of neurology.of Leqembi, a drug from Eisai and partner Biogen that removes amyloid from the brain and has been shown to slow the advance of Alzheimer's in early-stage patients.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Quest Diagnostics launches Alzheimer's blood test for consumersQuest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.
Read more »
Lady Gaga Mourns 'Painful' But 'Beautiful' Loss of Tony BennettLady Gaga is reflecting on her late friend and collaborator Tony Bennett in a touching tribute.
Read more »
N.J. has 6th highest rate of Alzheimer’s among seniors in nation, study findsAn estimated 185,000 New Jersey residents have Alzheimer's disease, a brain disorder that slowly destroys memory, thought and language.
Read more »
Texas Alzheimer’s patient calls new treatment life-changingThese past few years are being called a major tipping point in Alzheimer's research. A second treatment has now been approved that targets the underlying cause of Alzheimer's, not just the symptoms.
Read more »
Insight: Promising new Alzheimer's drugs may benefit whites more than BlacksGroundbreaking treatments for Alzheimer's disease that work by removing a toxic protein called beta amyloid from the brain may benefit whites more than Black Americans, whose disease may be driven by other factors, leading Alzheimer's experts told Reuters.
Read more »
Putting the brakes on Alzheimer’s disease⭐Research highlight: In a phase 3 trial, the monoclonal antibody donanemab (which clears amyloid plaques) slowed clinical progression of early symptomatic Alzheimersdisease. JAMA_current
Read more »